This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Mapping the conformational energy landscape of Abl kinase using ClyA nanopore tweezers
Nature Communications Open Access 20 June 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190–2196.
Azam M, Latek RR, Daley GQ . Mechanisms of autoinhibition and STI-571/Imatinib resistance revealed by mutagenesis of BCR–ABL. Cell 2003; 112: 831–843.
Hantschel O, Superti-Furga G . Regulation of the c-Abl and bcr–abl tyrosine kinases. Nat Rev Mol Cell Biol 2004; 5: 33–45.
Goldman JM . Chronic myeloid leukemia-still a few questions. Exp Hematol 2004; 32: 2–10.
Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276–283.
Corbin AS, Buchdunger E, Pascal F, Druker BJ . Analysis of the structural basis of specificity of inhibition of the ABL kinase by STI571. J Biol Chem 2002; 27: 32214–32219.
Warmuth M, Simon N, Mitina O, Mathes R, Fabbro D, Manley PW et al. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood 2003; 101: 664–672.
Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW . Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003; 101: 4611–4614.
Acknowledgements
This work was supported by ‘Ligue contre le cancer’ and ‘Association pour la Recherche contre le Cancer’.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Leguay, T., Desplat, V., Lagarde, V. et al. An amino-acid switch in the BCR-ABL kinase domain modifies sensitivity to imatinib mesylate. Leukemia 19, 1671–1673 (2005). https://doi.org/10.1038/sj.leu.2403831
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403831
This article is cited by
-
Mapping the conformational energy landscape of Abl kinase using ClyA nanopore tweezers
Nature Communications (2022)